Janiczek-Polewska Marlena, Szylberg Łukasz, Malicki Julian, Marszałek Andrzej
Department of Electroradiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
Department of Clinical Oncology, Greater Poland Cancer Center, 61-866 Poznan, Poland.
Biomedicines. 2022 Jul 5;10(7):1600. doi: 10.3390/biomedicines10071600.
Gastric cancer (GC) is the fourth most common cancer in the world in terms of incidence and second in terms of mortality. Chemotherapy is the main treatment for GC. The greatest challenge and major cause of GC treatment failure is resistance to chemotherapy. As such, research is ongoing into molecular evaluation, investigating mechanisms, and screening therapeutic targets. Several mechanisms related to both the tumor cells and the tumor microenvironment (TME) are involved in resistance to chemotherapy. TME promotes the secretion of various inflammatory cytokines. Recent studies have revealed that inflammatory cytokines affect not only tumor growth, but also chemoresistance. Cytokines in TME can be detected in blood circulation and TME cells. Inflammatory cytokines could serve as potential biomarkers in the assessment of chemoresistance and influence the management of therapeutics in GC. This review presents recent data concerning research on inflammatory cytokines involved in the mechanisms of chemoresistance and provides new clues in GC treatment.
胃癌（GC）在全球癌症发病率中位列第四，死亡率位列第二。化疗是胃癌的主要治疗方法。胃癌治疗失败的最大挑战和主要原因是对化疗产生耐药性。因此，目前正在进行分子评估、机制研究以及治疗靶点筛选等方面的研究。与肿瘤细胞和肿瘤微环境（TME）相关的多种机制都参与了化疗耐药过程。肿瘤微环境促进多种炎性细胞因子的分泌。最近的研究表明，炎性细胞因子不仅影响肿瘤生长，还影响化疗耐药性。肿瘤微环境中的细胞因子可在血液循环和肿瘤微环境细胞中检测到。炎性细胞因子可作为评估化疗耐药性的潜在生物标志物，并影响胃癌治疗方案的制定。本综述介绍了有关参与化疗耐药机制的炎性细胞因子研究的最新数据，并为胃癌治疗提供了新线索。
